Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
becotatug vedotin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Lepu Biopharma
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Becotatug vedotin + gemcitabine is a combination therapy consisting of an antibody-drug conjugate (ADC) and a nucleoside analog chemotherapy. Becotatug vedotin (MRG003) is an ADC targeting the epidermal growth factor receptor (EGFR), composed of a humanized IgG1 monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker. Gemcitabine is a standard-of-care chemotherapy that acts as a nucleoside analog to inhibit DNA synthesis. This combination is primarily being investigated for the treatment of second-line advanced pancreatic ductal adenocarcinoma (PDAC), a setting where EGFR is frequently overexpressed. The regimen aims to combine the targeted delivery of a potent cytotoxic payload with systemic chemotherapy to overcome resistance and improve clinical outcomes in patients who have progressed on first-line therapy.
- Brand names
- Meiyouheng + gemcitabine
- Other names
- becotatugvedotin plus gemcitabine
02
Targets
DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on becotatug vedotin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on becotatug vedotin + gemcitabine.